Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia: An Overview of Systematic Reviews

Table 1

Characteristics of included reviews.

Author (y)	Number of included articles	Number of patients	Type of patients	Intervention	Comparison	Outcome
Hoffman (2021) [36]	12	1928	Children or adolescents under the age of 21 with the first relapse of AML	Allo-SCT, auto-SCT, undefined type of SCT	Chemotherapy	abcd
Li (2019) [27]	11	1133	Patients with intermediate-risk AML in CR1	Auto-SCT	Allo-SCT	befg
Rashidi (2016) [28]	13	749	>60 years AML patients	Allo-SCT	Further chemotherapy or no treatment	Be (6 months, 1, 2, 3 years)
Ma (2015) [25]	9	772	FLT3/ITD AML patients	Allo-SCT	Auto-SCT, chemotherapy	bcg
Li (2015) [26]	9	1950	Patients with intermediate-risk AML in CR1	Allo-SCT	Nonallo-SCT (auto-SCT/chemotherapy)	befg
Wang (2010) [29]	13	3027	AML patients in CR1	Auto-SCT	Further chemotherapy or no treatment	bcfg
Krauter (2009) [30]	8	180	<60 years old with AML patients and reciprocal translocations involving chromosome band 11q23 [t (11q23)]	Allo-SCT	Chemotherapy or auto-SCT	be
Koreth (2009) [31]	24	6007	AML patients in CR1	Allo-SCT	Nonallo-SCT (auto-SCT/chemotherapy)	be
Schaich (2007) [32]	8	131	AML patients (median age 50 (18–60) years) exhibiting trisomy8 within a noncomplex karyotype	High-dose cytarabine + allo-SCT/auto-SCT	High-dose cytarabine	be
Nathan (2004) [33]	6	1044	Adult patients with AML	Autologous bone marrow transplantation (ABMT)	Nonmyeloablative chemotherapy or no further treatment	bc
Levi (2004) [34]	6	4110	AML patients in CR1	ABMT	Chemotherapy	bd
Bleakley (2002) [35]	10	2200	Pediatric AML patients in CR1	ABMT	BMT(with a matched sibling donor)/nonmyeloablative chemotherapy	bcdfg

a: CR2, second complete remission; b: OS, overall survival; c: DFS, disease-free survival; d: EFS, event-free survival; e: RFS, relapse-free survival; f: TRM, treatment-related mortality; g: RR, relapse rate.